Method and pharmaceutical composition for treating depression
11471428 · 2022-10-18
Assignee
Inventors
Cpc classification
G01N33/6872
PHYSICS
A61K31/4015
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
A61K31/4184
HUMAN NECESSITIES
A61K31/4184
HUMAN NECESSITIES
G01N2333/70571
PHYSICS
A61K31/135
HUMAN NECESSITIES
A61K31/135
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61K31/662
HUMAN NECESSITIES
A61K31/662
HUMAN NECESSITIES
International classification
A61K31/135
HUMAN NECESSITIES
A61K31/4015
HUMAN NECESSITIES
Abstract
A method for treating a subject with depression characterized by having an increased burst firing in neurons of a lateral habenula in the subject is provided. The method includes a step of administering to the subject a pharmaceutical composition capable of inhibiting the burst firing in the lateral habenula of the subject. The pharmaceutical composition includes one or more active pharmaceutical agents, which can suppress the burst firing in the lateral habenula of the subject and can include at least one of an N-methyl-D-aspartate receptor (NMDAR) inhibitor or a T-type calcium channel inhibitor. The pharmaceutical composition can be in a formulation allowing for local administration to the lateral habenula of the subject, or can be in a formulation configured for systemic administration to the subject. A method for testing a test substance for an antidepressive effect is also provided.
Claims
1. A method for treating a depression in a subject, comprising: examining whether neurons of a lateral habenula (LHb) of the subject have an increased burst firing; and if so, administering to the subject a pharmaceutical composition that inhibits the burst firing in the LHb of the subject, wherein the pharmaceutical composition comprises at least one of an N-methyl-D-aspartate receptor (NMDAR) inhibitor or a T-type calcium channel inhibitor.
2. The method of claim 1, wherein the administering to the subject a pharmaceutical composition that inhibits the burst firing in the LHb of the subject comprises: administering the pharmaceutical composition locally to the LHb of the subject.
3. The method of claim 1, wherein the administering to the subject a pharmaceutical composition that inhibits the burst firing in the lateral habenula of the subject comprises: administering the pharmaceutical composition systemically to the subject.
4. The method of claim 1, wherein the pharmaceutical composition comprises an N-methyl-D-aspartate receptor (NMDAR) inhibitor.
5. The method of claim 4, wherein the NMDAR inhibitor is a competitive NMDA receptor inhibitor, a non-competitive NMDA receptor inhibitor, an uncompetitive NMDA receptor channel blocker, or a glycine binding site inhibitor.
6. The method of claim 1, wherein the pharmaceutical composition comprises a T-type calcium channel inhibitor.
7. The method of claim 6, wherein the T-type calcium channel inhibitor is a succinimide, a hydantoin, zonisamide, sodium valproate, phenytoin, mibefradil, sipatrigine, a piperazine analogue, a piperidine analogue, TTA-P1, TTA-P2, quinazolinone, pimozide, trimethadione, dimethadione, TTA-Q4, or ML218.
8. The method of claim 1, wherein the pharmaceutical composition comprises an N-methyl-D-aspartate receptor (NMDAR) inhibitor and a T-type calcium channel inhibitor.
9. The method of claim 8, wherein a dose of one or both of the NMDA receptor inhibitor and the T-type calcium channel inhibitor is lower than an effective dose thereof when administered alone.
10. The method of claim 1, wherein the pharmaceutical composition does not inhibit tonic firing in the lateral habenula of the subject.
11. The method of claim 1, wherein the pharmaceutical composition allows for fast-acting treatment of the depression.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
DETAILED DESCRIPTION
(11) The technical details and benefits of the invention provided in the present disclosure are further described in the following examples, which are intended to illustrate the inventions and not to limit the scope of the present disclosure.
Example 1. Materials and Methods
(12) Animals. Male cLH rats (8-16 weeks of age) and age-matched male Sprague Dawley rats (SLAC Laboratory Animal Co., Shanghai) were used. The cLH rats were screened by learned helpless test for breeding as previously described (Schulz et al., 2010). Male adult (8-16 weeks of age) C57BL/6 mice (SLAC) were used for establishing the chronic restraint stress (CRS) depression model. Rats were group-housed two/cage and mice were four/cage respectively under a 12-h light-dark cycle (light on from 7 a.m. to 7 p.m.) with free access to food and water ad libitum. All animal studies and experimental procedures were approved by the Animal Care and Use Committee of the animal facility at Zhejiang University.
(13) Viral vectors. AAV2/9-CaMKII-eNpHR3.0-eYFP (titer: 7.45×10.sup.12 v.g./ml, dilution: 1:5, 0.1 μl unilateral into LHb, Taitool Bioscience, China), AAV2/9-Ubi-eGFP (titer: 2.5×10.sup.13 v.g./ml, 1:30, 0.1 μl each side of LHb, University of Massachusetts, Guangping Gao Lab, USA), AAV2/9-hSyn-oChIEF-tdTomato (titer: 6.29×10.sup.12 v.g./ml, 1:5, 0.1 μl unilateral into LHb, Obio Technology, Shanghai, Corp., Ltd) were aliquoted and stored at −80° C. until use.
(14) Cannula infusion experiment. A 26-gauge double guide cannulae (center-to-center distance 1.4 mm, Plastics One) was placed with a 2-degree angle with coronal plane (without the 2 degree rotation, we found it difficult to hit both sides of LHb) and inserted bilaterally into the LHb (AP, −3.7 mm from bregma; ML, ±0.7 mm; DV, −4.1 mm from the brain surface) of cLH rats. A 33-gauge double dummy cannulae (Plastic One), secured with a dust cap, was inserted into guide cannula to prevent clogging during recover period. After rats were recovered for at least 7 days, drugs were microinjected with a 33-gauge double injector cannulae, which has a 0.6 mm extension beyond the tip of the guide cannula, while cLH rats were anaesthetized with isoflurane on an anesthetic machine. The extensions were manually sharpened before insertion.
(15) Ketamine (25 μg/μl), AP5 (40 nmol/μl, IC50=30 μM), NBQX (1 nmol/μl, IC50=0.15 μM) or mibefradil (10 nmol/μl) were dissolved in 0.9% saline respectively. Ketamine was purchased from Gutian Pharma Co., Fujian, and stored at room temperature. Before the drug local infusion, tip-sharpened 33-gauge double injector cannulae were inserted into the guide cannulae to assure clear passage and then pulled out. 1 μl of drug was infused (0.1 μl/min) into each side through another tip-sharpened 33-gauge double injector cannulae, which were connected to the microsyringe. The injector cannulae were left in place for an additional 10 min to minimize spread of the drug along the injection track. FST or SPT was performed 1 h after the injection of ketamine or mibefradil, 0.5 h after the injection of AP5 or NBQX. To verify the drug infusion sites, rats were injected with 1 μl CTB-488 to each side of LHb after all behavioral tests. For immunostaining, rats were then euthanized 30 min after CTB injection and processed as described. Brain slices were counterstained with Hoechst before mounting on the slides. Fluorescent image acquisition was performed with an Olympus VS120® virtual microscopy slide scanning system. Only data from rats with correct injections were used.
(16) LHb brain slice preparation. Animals (P45-70 rats and P65-75 mice) were anesthetized with isoflurane and 10% chloral hydrate, and then perfused with 20 ml ice-cold ACSF (oxygenated with 95% O.sub.2+5% CO.sub.2) containing (mM): 125 NaCl, 2.5 KCl, 25 NaHCO.sub.3, 1.25 NaH2PO4, 1 MgCl.sub.2 and 25 Glucose, with 1 mM pyruvate added. The brain was removed as quickly as possible after decapitation and put into chilled and oxygenated ACSF. Coronal (for most of experiments if not specified) or sagittal slices containing habenular (350 μm- and 300 μm-thickness for rats and mice, respectively) were sectioned in cold ACSF by a Leica2000 vibratome and then transferred to ASCF at 32° C. for incubation and recovery. ACSF was continuously gassed with 95% O.sub.2 and 5% CO.sub.2. Slices were allowed to recover for at least 1 hour before recording. For cLH rats, since a very high percentage (90%) of cLH offsprings are learned helpless, we did not perform LH test before taking them for brain slice recording. For CRS mice, both CRS and their wild-type controls went through FST test before brain slice recording. We then used the CRS animals which showed high immobility scores (immobile time >140 s) and control mice which showed low immobility (immobile time <110 s) in FST for slice recording.
(17) In vitro Electrophysiological recording. For LHb neuron recordings, currents were measured under whole-cell patch clamp using pipettes with a typical resistance of 5-6 MΩ filled with internal solution containing (mM): 10.sup.5 K-Gluconate, 30 KCl, 4 Mg-ATP, 0.3 Na-GTP, 0.3 EGTA, 10 HEPES and 10 Na-phosphocreatine, with pH set to 7.35. The external ACSF solution contained (in mM) 125 NaCl, 2.5 KCl, 25 NaHCO.sub.3, 1.25 NaH.sub.2PO.sub.4, 1 MgCl.sub.2, 2 CaCl.sub.2 and 25 Glucose. Cells were visualized with infrared optics on an upright microscope (BX51WI, Olympus). A MultiClamp 700B amplifier and pCLAMP10 software were used for electrophysiology (Axon Instruments). The series resistance and capacitance was compensated automatically after stable Giga seal were formed. Recordings were typically performed between 3-6 min after break-in. The spontaneous neuronal activity was recorded under current-clamp (I=0 pA).
(18) LHb neurons display three modes of spontaneous activity at resting conditions. Silent cells showed no spike activities during recording. Tonic cells spontaneous generated tonic trains of action potentials at frequency between 0.1-10 Hz, rarely up to 10-20 Hz. Burst-firing cells spontaneously generate clusters of spikes with an initially high but progressively declining intra-burst firing frequency in each burst. For bursting neurons, 99% (from n=50 bursting neurons) of their spikes occurred within bursts.
(19) Evoked-NMDAR-EPSC was recorded under voltage clamp from −50 mV to −80 mV in a modified extracellular ACSF solution with 0 Mg.sup.2+. Evoked T-type VSCC current was recorded under voltage clamp starting from a holding potential of −50 mV before increased to conditioning potential (−100 mV) for is preceding the command steps (5 mV, 0.1 Hz/step increment). LHb T-VSCC currents were obtained by subtraction of recorded traces in presence or absence of mibefradil.
(20) In vivo electrophysiology. For in vivo recording experiments, a custom-made microdrive array consisting of 8 tetrodes (impedance 250-500 KΩ, California fine wire) was implanted in LHb (AP, −1.72 mm; ML, 0.46 mm; DV, −2.44 mm from the brain surface) of Ctrl or CRS mice. Stainless steel wires were attached to two screws on the skull as ground. The microdrive was secured to the skull with dental cement. After recovery for 2 weeks, mice were allowed to adapt to the recording headstage 10 min per day for 2-3 days. Spontaneous spiking activity (digitized at 40 kHz, band-pass filtered between 300-6000 Hz) and LFP (digitized at 1 kHz sampling rate, low-pass filtered up to 250 Hz) were recorded simultaneously for 30 min during the still period of the mice in their home cages with a gain of 5000×. A single channel without detectable unit was assigned as a reference electrode. The tetrodes were lowered insteps of 70 μm after each recording session followed with at least 2 day-recovery. For CRS mice, data were recorded for 30 min before and 1 h after ketamine treatment (10 mg/kg, i.p.). If mice received a second ketamine injection, at least a 2-week interval was introduced before the next recording session. All procedures were performed during the light phase. The positions of the electrodes were verified by electrolytic lesions (30 μA, 10-15 s) at the end of all the experiments.
(21) Spike sorting. All waveforms recorded from each tetrode were imported in Offline Sorter V3 (Plexon Inc.). Single units were manually identified by threshold crossing and principal component analysis (PCA). Spikes with inter-spike interval (ISI) less than the refractory period (1.4 ms) were excluded. Cross correlograms were plotted to ensure that no cell was discriminated more than once on overlapping tetrodes. Only units with signal to noise ratio larger than 2 were used.
(22) Behavioral assays. All behavioral assays were performed on animals 12-16 weeks old, in the light cycle (7:00-19:00) except for the sucrose preference test, which was performed during dark phase to maximize the consumption of solutions. Behavioral analysis was performed blindly.
(23) Forced swim test (FST). Animals were individually placed in a cylinder (12 cm diameter, 25 cm height for mice; 20 cm diameter, 50 cm height for rats) of water (23-24° C.) and swam for 6 min under normal light. Animal behaviors were videotaped from the side. The immobile time during the last 4 min test was counted offline by an observer blind of the animal treatments. Immobile time was defined as time when animals remained floating or motionless with only movements necessary for keeping balance in the water. For rats, an additional pre-test was conducted 24 h before the test, during which rats were individually placed in a cylinder of water with conditions described above for 15 min. For optogenetic manipulations, laser stimulation was turned on as previously described, immediately after mice were placed in the water and lasted for 6 min. In order to minimize the impact of the optogenetic cable on swimming behavior, the cable length was adjusted to allow the cable just touch the water surface.
(24) Sucrose preference test (SPT). Animals were single housed and habituated with two bottles of water for 2 days, followed by two bottles of 2% sucrose for 2 days. Animals were then water deprived for 24 h and then exposed to one bottle of 2% sucrose and one bottle of water for 2 h in the dark phase. Bottle positions were switched after 1 h. Total consumption of each fluid was measured and sucrose preference was defined as the ratio of sucrose consumption divided by total consumptions of water and sucrose. For optogenetic manipulations, mice were gently placed in a white arena containing normal bedding and allowed to freely move in the arena. During the 90-min test, light was delivered during 30-60 min. Laser intensity during eNpHR3.0 stimulation was adjusted to 10 mW since LHb neurons could not follow 16 mW stimulation for longer than 10 min. Sucrose preference scores were measured for every 30 min. Only animals that had a >30% baseline sucrose preference during the first 30 min session would proceed to the next session. Otherwise they would be tested later on a different day. Behavioral analyses and experiments were performed blindly.
(25) Chronic restraint stress (CRS). Mice were subjected to chronic-restraint stress by placement in 50-ml conical tubes with holes for air flow for 2-3 hours per day for 14 consecutive days. ROC curve (Receiver Operating Characteristic curve) of immobile time in forced-swim test was used to assess the successful rate of CRS on depressive-like behaviors. The nearest point to (0, 100) on ROC curve was selected as successful rate according to GraphPad Statistics Guide.
(26) Real-time place aversion. Mice were placed in a white open chamber (52 cm×26 cm×23 cm) consisting of two chambers, and allowed to freely move between chambers for 20 minutes to assess their baseline place preference. During the following 20-min test, we assigned a stimulated side with a counterbalanced manner. Laser stimulation was turned on as previously described, as soon as mice entered the stimulated side and terminated once mice crossed to the non-stimulated side. A video camera positioned above the chamber recorded each trial. Mouse locations and velocity were tracked and analyzed using Any-maze Software (Stoelting Co.). Avoidance score=(Time in stimulated side−Time in non-stimulated side).sub.test−(Time in stimulated side−Time in non-stimulated side).sub.baseline
(27) Open field test (OFT). Animals were placed in the center of an arena (40 cm×40 cm×40.5 cm for mice; and 100 cm×100 cm×50 cm for rats) in a room with dim light for 6 min. A video camera positioned directly above the arena was used to track the movement of each animal (Any-maze, Stoelting, US). For optogenetic manipulations, mice were allowed to freely move throughout the arena for 9 min, with laser stimulation occurring during the middle 3 min epoch (eNpHR3.0: 589 nm, 1 Hz, 16 mW, 100 ms pulses; oChIEF: 473 nm, 100 Hz, 25 mW, either 5 ms pulses, 5 pulses/s for the pulsed 100 Hz protocol or 5 Hz, 5 ms pulses for the 5 Hz protocol).
(28) Statistical analysis. Required sample sizes were estimated based on our past experience performing similar experiments. Mice were randomly assigned to treatment groups. Analysis were performed in a manner blinded to treatment assignments in all behavioral experiments. Statistical analyses were performed using GraphPad Prism software v6. By pre-established criteria, values were excluded from the analyses if the viral injection or drug delivering sites were out of LHb. All statistical tests were two-tailed, and significance was assigned at P<0.05. Normality and equal variances between group samples were assessed using the D'Agostino & Pearson omnibus normality test and Brown-Forsythe tests respectively. When normality and equal variance between sample groups was achieved, one-way ANOVAs (followed by Bonferroni's multiple comparisons test), or t test were used. Where normality or equal variance of samples failed, Kruskal-Wallis one-way ANOVAs (followed by Dunn's correction), Mann-Whitney U test, or Wilcoxon matched-pairs signed rank test were performed. Linear regression test, Chi-square test, Fisher's exact test or two-way ANOVAs (followed by Bonferroni's multiple comparisons test) was used in appropriate situations.
Example 2. Local Blockade of NMDARs in LHb is Sufficient to be Rapid Antidepressant
(29) The antidepressant effect of ketamine was tested on a well-accepted animal model of depression, the congenitally learned helpless (cLH) rats. It was tested whether ketamine may exert its antidepressant effect through LHb by performing bilateral infusion of ketamine in the LHb through dual guide cannulae (
Example 3. Three Types of LHb Neurons, the Silent, Tonic and Burst Firing Types
(30) To investigate the activity pattern of the LHb neurons, whole cell patch clamp is performed in the LHb coronal slices, and recorded spontaneous neuronal activity under current clamp at resting conditions (I=0 pA). It was found that LHb neurons were intrinsically active and fell into three categories, namely, the silent, tonic- and burst-firing types (
(31) The resting membrane potentials (RMPs) of LHb neurons were on average more depolarized than those in the hippocampus or cortex (
(32) To test the potential contribution of bursting activity in the hyperactive state of the LHb under depression, the spike patterns of LHb neurons from the cLH or wild type SD rats were compared. While the percentage of bursting neurons was significantly increased from 7% (n=8/121) in the SD controls to 23% (n=21/102) in the cLH rats (
(33) To test if enhanced bursting is universal in depression, we used a second animal model of depression, mice with chronic restraint stress (CRS). Patch clamp recording of LHb neurons in these mice revealed similar phenomena, namely, percentage of bursting cells and percentage of spikes in bursting were both dramatically increased (
Example 4. Ketamine Suppresses Enhanced LHb Bursting Activity and Theta-Band Synchronization In Vivo in Chronic Restraint Mice
(34) To test whether burst also occurs in vivo in the LHb and whether it is bidirectionally modulated by depression state and ketamine, in vivo multi-tetrode recording was performed in the LHb of freely behaving mice (
(35) Burst firing was known to increase network synchronization. It was thus tested whether LHb network synchronization was altered in the CRS animals. It was first calculated the spike-triggered averages (STAs) of local field potential (LFP), which revealed oscillatory synchronization between spikes and LFP. In the control mice, the distribution of the power spectra of STAs was relatively flat (
(36) Together with the in vitro slice experiments, these in vivo results in freely behaving animals provide strong evidences that LHb bursting is pathologically enhanced in depression, which can be efficiently alleviated by ketamine.
Example 5. Bursts in LHb Directly Require Activation of NMDAR
(37) Given that NMDAR-mediated calcium influx plays a pivotal role in burst generation in several brain regions, and in light of the data that systematic injection of ketamine suppressed bursting activity (
(38) To further verify the causal link between NMDAR activity and LHb bursting, we perfused NMDA (20 μM) onto the LHb brain slice in the presence of AMPAR blocker NBQX and GABAR blocker picrotoxin and 0 Mg.sup.2+ to activate NMDARs. NMDA application induced strong bursting activity in 10 out of 13 originally silent LHb neurons (
Example 6. Bursts in LHb Also Depend on Hyperpolarization and Synergistic Activation of T-VSCCs
(39) Given the correlation between the RMPs and firing mode of LHb neurons, we next tested whether changing RMPs can alter the pattern of spiking activity in LHb. By applying a transient ramp-like current injection enabling RMPs to change progressively from around −80 to −40 mV (
(40) This voltage-dependent transition of firing mode also occurred in spontaneously-spiking LHb neurons. By delivering a hyperpolarizing current injection (−10˜−20 pA), 75% of originally tonic-firing neurons could be transformed to burst-firing mode (
(41) Since NMDAR alone does not explain the voltage-dependence of LHb bursts, we searched for more ion channels involved. The T-type Voltage Sensitive Calcium Channels (T-VSCCs, including Cav3.1, 3.2, 3.3) are known to have pacemaker activity and are expressed in LHb neurons. Unlike other types of voltage sensitive calcium channels, T-VSCCs are inactivated quickly after opening at depolarized membrane potentials, but can be de-inactivated to initiate burst firings when the membrane potential is hyperpolarized for longer than 100 ms. Bath application of mibefradil (10 μM), onto the LHb brain slices effectively decreased the bursting probability and reduced the amplitude of plateau potential of spontaneous bursts (
(42) To understand how NMDARs and T-VSCCs work synergistically to mediate LHb burst firing, we constructed a minimal biophysical model incorporating these two channels (
Example 7. Local LHb Blockade of T-VSCCs is Rapidly Anti-Depressive
(43) The above results predict that drugs blocking T-VSCCs may be also antidepressant. To test that, we performed bilateral infusion of a selective T-VSCC blocker, mibefradil (10 nmol, 1 ul each side), in the LHb of cLH rats through dual guide cannulae (
Example 8. NpHR-Induced Rebound Burst Drives Behavioral Aversion and Depressive-Like Symptoms
(44) Based on the observation that a hyperpolarization ramp current could induce burst firing in the LHb (
(45) It was then tested whether the rebound bursts in the LHb could acutely drive aversion and depressive-like symptoms in freely behaving mice. In the real-time place aversion (RTPA) assay, 1 Hz yellow light photostimulation significantly reduced the time spent in the light-paired chamber in mice injected with AAV-eNpHR3.0 but not those with AAV-eGFP (
(46) To prove that it is the bursting firing mode but not the general increase in firing rate that is important for the induction of depressive-like behaviors, we applied a stimulation protocol (5 Hz on AAV-oChIEF injected mice) that yields the same overall firing rate as the rebound burst protocol (
(47) Collectively, these results indicated that bursting activity in the LHb can acutely drive depressive-like state.
Example 9. Co-Administration of Subeffective Antidepressant Doses of NMDAR Antagonist and T-VSCC Antagonist has an Antidepressant-Like Effect
(48) Low dose ketamine (one of the NMDAR antagonists, 2.5 mg/kg) or ethosuximide (ETH, one of the T-VSCC antagonists, 100 mg/kg) is ineffective in the forced swim test in C56BL/6 mice 1 hour after drug administration (i.p.) (
(49) These above in vivo experiments suggest that administering an NMDA receptor inhibitor at a dosage lower than its working dosage in combination with administering a T-VSCC receptor inhibitor at a dosage lower than working dosage, could be effective in generating a significant anti-depression effect.
Example 10. Pharmacological Manipulations of Hyperpolarization-Triggered Rebound Bursts in LHb
(50) To further test the effect of NMDAR inhibitors combined with T-VSCC inhibitors on the induction of burst firing, the effects on inducing burst firing by NMDAR inhibitors and T-VSCC inhibitors alone or in combination were tested.
(51) Based on the observation that a hyperpolarization ramp current could induce burst firing in the LHb, a protocol was devised employing a transient (100 ms) hyperpolarization current injection, which induced rebound bursts in the LHb brain slices with 100% success rate (
(52) When the lateral habenular slices were perfused with ketamine (100 μM,
(53) Thus in other words, the hyperpolarization-induced rebound bursts can be partially inhibited by ketamine (100 μM,
(54) Collectively, these above in vitro experiments demonstrate that a combination of a low dose of an NMDA receptor inhibitor that is lower than the effective dose when administered alone and a low dose of a T-VSCC receptor inhibitor that is also lower than the effective dose when administered alone can produce a much more pronounced and significant antidepressant effect. It is also noteworthy that since the lower than effective doses of the NMDA receptor inhibitor and the T-VSCC receptor inhibitor are administered, there is potentially another benefit for a reduced side effect for both drugs.
(55) Unless otherwise indicated, the practice of the present disclosure will employ common technologies of organic chemistry, polymer chemistry, biotechnology, and the like. It is apparently that in addition to the above description and examples than as specifically described, the present disclosure can also be achieved in other ways. Other aspects within the scope of the disclosure and improvement of the present disclosure will be apparent to the ordinary skilled in the art. According to the teachings of the present disclosure, many modifications and variations are possible, and therefore it is within the scope of the present disclosure.
(56) Unless otherwise indicated herein, the temperature unit “degrees” refers to Celsius degrees, namely ° C.
(57) All references that have been referred to in the present application are incorporated by reference in their entirety.
REFERENCES
(58) 1. GraphPad Statistics Guide: http://www.graphpad.com/guides/prism/7/statistics/index.htm. 2. Li et al. Nature 470, 535-539, 2011. 3. Li et al., Science 341, 1016-1020, 2013. 4. Schulz et al., Neurobiol Learn Mem 93, 291, February 2010. 5. Yang et al. Nature 554, 317-322, 2018.